---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-007548"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:30.060413+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent

## Summary
- Moderna to pay $950M non-contingent by July 8, 2026; additional $1.3B if Federal Circuit affirms rejection of Section 1498 defense.
- Settlement includes judgment of no invalidity on four Genevant/Arbutus patents and a global non-exclusive license to LNP tech for infectious disease mRNA vaccines.
- Roivant board authorizes $1B share repurchase program (includes prior $500M authorization), no expiration date.
- Genevant/Arbutus continues litigation against Pfizer/BioNTech; Comirnaty sales represent ~2/3 of global COVID mRNA vaccine sales.

## SEC filing metadata
- accession: 0001140361-26-007548
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-007548
- JSON: https://secwatch.observer/filing/0001140361-26-007548.json
- Plain text: https://secwatch.observer/filing/0001140361-26-007548.txt

## Source-grounded claims
- claim_id: 45627f24230e0c946323db9cced6e1d3a2d9fede
  claim: Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).
  evidence_excerpt: On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.